Erratum to: Bone density in proton pump inhibitors users: a prospective study (Rheumatology International, (2013), 33, (2255-2260), 10.1007/s00296-013-2709-0);Bone density in proton pump inhibitors users: A prospective study

Rheumatology International

Volumn 33, Issue 9, 2013, Pages 2255-2260

  Ozdil, Kamil ^a   Kahraman, Resul ^a   Sahin, Abdurrahman ^a   Calhan, Turan ^a   Gozden, Erdem H ^a   Akyuz, Umit ^b   Erer, Burak ^c   Sokmen, Mehmet H ^a  

^a Umraniye Training and Research Hospital   (Turkey)

^b FATIH SULTAN MEHMET TRAINING AND RESEARCH HOSPITAL   (Turkey)

^c ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Bone density; Gastroesophageal reflux disease; Proton pump inhibitors

Indexed keywords

ESOMEPRAZOLE; LANSOPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR;

ADULT; ARTICLE; BONE DENSITOMETRY; BONE DENSITY; BONE MINERAL; CLINICAL ASSESSMENT; CONTROLLED STUDY; DRUG USE; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR NECK; FRACTURE; GASTROESOPHAGEAL REFLUX; HUMAN; LONG TERM CARE; LUMBAR SPINE; LUMBAR VERTEBRA; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIDE EFFECT; TREATMENT DURATION;

ADOLESCENT; ADULT; BONE DENSITY; FEMALE; GASTROESOPHAGEAL REFLUX; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROTON PUMP INHIBITORS;

EID: 84883198093     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-016-3554-8     Document Type: Erratum

References (21)

1. Mazziotti G, Canalis E, Giustina A (2010) Drug-induced osteoporosis: mechanisms and clinical implications. Am J Med 123(10):877-884. doi: 10.1016/j.amjmed.2010.02.028
2. Graziani G, Badalamenti S, Como G, Gallieni M, Finazzi S, Angelini C, Brancaccio D, Ponticelli C (2002) Calcium and phosphate plasma levels in dialysis patients after dietary Ca-P overload. Role of gastric acid secretion. Nephron 91(3):474-479
3. O'Connell MB, Madden DM, Murray AM, Heaney RP, Kerzner LJ (2005) Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. Am J Med 118(7):778-781. doi: 10.1016/j.amjmed.2005.02.007
4. Yang YX (2008) Proton pump inhibitor therapy and osteoporosis. Curr Drug Saf 3(3):204-209
5. Gagnemo-Persson R, Samuelsson A, Hakanson R, Persson P (1997) Chicken parathyroid hormone gene expression in response to gastrin, omeprazole, ergocalciferol, and restricted food intake. Calcif Tissue Int 61(3):210-215
6. Tuukkanen J, Vaananen HK (1986) Omeprazole, a specific inhibitor of H+-K+-ATPase, inhibits bone resorption in vitro. Calcif Tissue Int 38(2):123-125
7. Yang YX, Lewis JD, Epstein S, Metz DC (2006) Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 296(24):2947-2953. doi: 10.1001/jama.296.24.2947
8. de Vries F, Cooper AL, Cockle SM, van Staa TP, Cooper C (2009) Fracture risk in patients receiving acid-suppressant medication alone and in combination with bisphosphonates. Osteoporos Int 20(12):1989-1998. doi: 10.1007/s00198-009- 0891-4
9. Vestergaard P, Rejnmark L, Mosekilde L (2006) Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int 79(2):76-83. doi: 10.1007/s00223-006-0021-7
10. Targownik LE, Lix LM, Metge CJ, Prior HJ, Leung S, Leslie WD (2008) Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ 179(4):319-326. doi: 10.1503/cmaj.071330
11. McGowan B, Bennett K, Barry M (2010) Prescribing of anti-osteoporotic therapies following the use of proton pump inhibitors in general practice. Pharmacoepidemiol Drug Saf 19(7):763-769. doi: 10.1002/pds.1972
12. Leslie WD, Tsang JF, Caetano PA, Lix LM (2007) Effectiveness of bone density measurement for predicting osteoporotic fractures in clinical practice. J Clin Endocrinol Metab 92(1):77-81. doi: 10.1210/jc.2006-1415
13. Sheikh MS, Santa Ana CA, Nicar MJ, Schiller LR, Fordtran JS (1987) Gastrointestinal absorption of calcium from milk and calcium salts. N Engl J Med 317(9):532-536. doi: 10.1056/NEJM198708273170903
14. Gray SL, LaCroix AZ, Larson J, Robbins J, Cauley JA, Manson JE, Chen Z (2010) Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative. Arch Intern Med 170(9):765-771. doi: 10.1001/archinternmed.2010.94
15. Corley DA, Kubo A, Zhao W, Quesenberry C (2010) Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients. Gastroenterology 139(1):93-101. doi: 10.1053/j.gastro.2010.03. 055
16. Karsdal MA, Henriksen K, Sorensen MG, Gram J, Schaller S, Dziegiel MH, Heegaard AM, Christophersen P, Martin TJ, Christiansen C, Bollerslev J (2005) Acidification of the osteoclastic resorption compartment provides insight into the coupling of bone formation to bone resorption. Am J Pathol 166(2):467-476. doi: 10.1016/S0002-9440(10)62269-9
17. Mattsson JP, Vaananen K, Wallmark B, Lorentzon P (1991) Omeprazole and bafilomycin, two proton pump inhibitors: differentiation of their effects on gastric, kidney and bone H(+)-translocating ATPases. Biochim Biophys Acta 1065(2):261-268
18. Mizunashi K, Furukawa Y, Katano K, Abe K (1993) Effect of omeprazole, an inhibitor of H+, K(+)-ATPase, on bone resorption in humans. Calcif Tissue Int 53(1):21-25
19. Yu EW, Blackwell T, Ensrud KE, Hillier TA, Lane NE, Orwoll E, Bauer DC (2008) Acid-suppressive medications and risk of bone loss and fracture in older adults. Calcif Tissue Int 83(4):251-259. doi: 10.1007/s00223-008-9170-1
20. Targownik LE, Lix LM, Leung S, Leslie WD (2010) Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology 138(3):896-904. doi: 10.1053/j.gastro.2009.11.014
21. Rejnmark L (2008) Cardiovascular drugs and bone. Curr Drug Saf 3(3):178-184